🧠 The cancer vaccine SurVaxM generated a clinically meaningful OS improvement vs placebo in newly diagnosed glioblastoma, although the SURVIVE trial did not reach its primary end point. @roswellpark.bsky.social #btsm #oncology
Full story ➡️: www.onclive.com/view/survaxm...
